NCT06732128 Nature-based Virtual Reality Intervention for Depression in Alzheimer's Disease
| NCT ID | NCT06732128 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre for Addiction and Mental Health |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-01-06 |
| Primary Completion | 2025-06-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-01-06 with a primary completion date of 2025-06-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Behavioural and psychological symptoms of dementia (BPSD), such as depression affect up to 90% patients with dementia. Non-pharmacological treatment of BPSD, can be difficult to access, require caregiver support, travel, and often have long waiting lists. Virtual reality (VR) is an innovative, portable, immersive, and accessible technology which can be used in-home. More information is required on the feasibility of using VR in-home with older adults with dementia. Our study will offer a 4-week program of 15-minutes sessions, twice per week nature-based VR program for BPSD delivered in-home by virtual reality (VR). Additionally, caregivers will have the option of taking part in the study and provide feedback regarding the VR intervention. If successful, this project has the potential to prolong aging in place for individuals with BPSD, as BPSD is a significant factor in institutionalization.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of mild to early-moderate stage AD (including mixed dementia with AD) using the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. Criteria * Age of 50 years or older * Medical stability to participate in the trial * Patient Health Questionnaire score 5-14 * Investigator judgement on whether the participant is comfortable with technology * Access to WiFi and a smart device for connecting on WebEx and downloading the Fitbit and Muse applications * Have someone available to be present during all sessions Exclusion Criteria: * Unstable medical or psychiatric condition, including substance use based on an investigator opinion * Visual or hearing impairments that would impair participation * Patient Health Questionnaire score 15-27 and/or score of 1 or 2 in section E question 1 of the Cornell Scale for Depression in Dementia * Any other reason, which will make the study participation intolerable for the participant in the opinion of the study investigator
Contact & Investigator
HARMEHR SEKHON, PhD
PRINCIPAL INVESTIGATOR
CAMH and McGill/St. Mary's Research Centre
Frequently Asked Questions
Who can join the NCT06732128 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06732128 currently recruiting?
Yes, NCT06732128 is actively recruiting participants. Contact the research team at ashnie.sukhu@camh.ca for enrollment information.
Where is the NCT06732128 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06732128 clinical trial?
NCT06732128 is sponsored by Centre for Addiction and Mental Health. The principal investigator is HARMEHR SEKHON, PhD at CAMH and McGill/St. Mary's Research Centre. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.